Clinical trial
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)
NCT04767802 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)
- Lead sponsor
- Protagonist Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 2, 2021
- Completion date
- March 15, 2023
- Enrollment
- 20 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.